drugset / Trial / NCT00508287

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes

NCT00508287

Phase 1 Completed 36 enrolled Bristol-Myers Squibb
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single doses of BMS-686117

Timeline

Start
2007-08
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-686117 Protein / enzyme biologic 1 mg Subcutaneous
Comparator Exenatide Peptide 5 ug Subcutaneous